This year's International Faculty includes:
- Dr Thomas Ahlering, Professor & Vice Chairman Department of Urology University of California, Irvine School of Medicine, USA
- Dr William J Catalona, Department of Urology, Chicago, USA
- Prof Noel Clarke, Professor of Urological Oncology, Manchester University, UK
- Dr Matthew Cooperberg, A/Prof, Depts of Urology & Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center USA
- Dr Martin Gleave, British Columbia Leadership Chair, Professor and Distinguished University Scholar, Department of Urologic Sciences, University of British Columbia, Director, The Vancouver Prostate Centre, Canada
- Dr Larry Goldenberg, University of British Columbia, Canada
- Dr Makarand V Khochikar, Siddhi Vinayak Ganapati Cancer Hospital, Miraj, India
- Dr Stacy Loeb, Assistant Professor of Urology and Population Health, New York University, USA
- Dr Vipul Patel, Director of Robotic Surgery, Professor of Urology, UCF, Director of Urologic Oncology, Florida Hospital Cancer Institute, USA
- Dr Tom Pickles, BC Cancer Agency, Canada
- Dr Monique Roobol, Erasmus University Medical Center, Department of Urology, Rotterdam, The Netherlands
- Dr Oliver Sartor, Tulane University School of Medicine, USA
- Dr Joseph A Smith, Professor and Chairman, Department of Urologic Surgery, Vanderbilt University, Nashville USA
- Dr Matthew Smith, Harvard Medical School, USA
- Dr Rainy Umbas, Asian School of Urology, Indonesia
- Dr Patrick C Walsh, University Distinguished Service Professor, The James Buchanan Brady Urological Institute, Johns Hopkins Medicine, USA.
Dr Thomas E. Ahlering, M.D. Professor of Urology and Vice Chairman, Department of Urology, University of California, USA
Dr. Ahlering received a B.S. in Chemistry from the University of California, Berkeley (1975) his M.D. at St. Louis University (1979) and residency in urology at the University of Southern California (1984) and fellowship in urologic oncology at USC under Dr. Donald Skinner and Peter Jones Ph.D (1986). From 1986-1992 Dr. Ahlering headed the Department of Urologic Oncology at the City of Hope and from 1992-2002 was Chief of the Division of Urology at the University of California, Irvine. In 2002 Dr. Ralph Clayman became Chairman and Dr. Ahlering - Vice Chairman. Dr. Ahlering has active research projects in prostate cancer, and has produced over 150 publications of journal articles and book chapters.
Dr William J Catalona, Department of Urology, Chicago, USA
Dr. Catalona joined the Northwestern faculty in 2003. He is known for having been the first to show that a simple blood test that measures levels of prostate-specific antigen (PSA) is the most accurate method for detecting prostate cancer and for having developed the "free" PSA test as a means of improving the accuracy of prostate cancer screening.
Dr. Catalona is currently conducting research into the genetics of prostate cancer which could lead to new tests for the disease as well as possible new means of treating or preventing prostate cancer. He specializes in prostate cancer surgery and is recognized as an expert in performing the "nerve-sparing" radical prostatectomy that can preserve sexual potency.
In addition to his appointment as Professor of Urology, Dr. Catalona also serves as Director of the Clinical Prostate Cancer Program of Northwestern's Robert H. Lurie Comprehensive Cancer Center.
Prof Noel Clarke, ChM FRCS (Urol), Professor of Urological Oncology, Manchester University, UK
Qualified 1981 (Lond). Consultant Urological Surgeon 1993-. Specialist in Urological Cancer and complex pelvic and retroperitoneal tumours.
Formerly: Director Urology/Surgery Salford Royal and Christie Hospitals, Chairman Greater Manchester Urological Cancer Network, Chair UK NCRI Prostate Clinical Studies Group from 2003 to 2009. Currently: Professor of Urological Oncology, Manchester University, Director Manchester University GU Cancer Research Group, director pan-Manchester MCRC biobank. Member UK Department of Health Prostate Cancer and the NCRN advisory boards, Deputy Chair EORTC GU Group, faculty member European School Urology.
Research encompassing basic science, translational studies, multiple Phase 2 / 3 trials in Urological Cancer. Multiple peer reviewed papers and book chapters on Urology and Urological cancer.
Dr Matthew Cooperberg, A/Prof, Depts of Urology & Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center USA
Matthew Cooperberg completed his undergraduate education at Dartmouth College and his medical and public health degrees at Yale University. He then completed his residency in urology and fellowship and urologic oncology at UCSF under Peter Carroll. He has multiple research interests, focusing in particular prostate cancer, and has published over 100 peer-reviewed publications in this area. His current areas of particular interest include biomarker validation, comparative effectiveness of treatment for localized prostate cancer, and evolving practice patterns for advanced disease. He maintains busy surgical practices at the UCSF Cancer Center and the San Francisco VA medical center, and lives in San Francisco with his family.
Dr Martin Gleave, British Columbia Leadership Chair, Professor and Distinguished University Scholar, Department of Urologic Sciences, University of British Columbia, Director, The Vancouver Prostate Centre, Canada
Dr Martin Gleave is a Distinguished Professor and Vice Chair of the Department of Urologic Sciences at the University of British Columbia (UBC), Director of the Vancouver Prostate Center, and a BC Leadership Chair. He has published > 340 papers with >14,000 citations, has an H-Index of 68, and attracted >$80M in research funding.
Dr. Gleave’s research characterizes molecular mechanisms mediating treatment resistance in cancer, focusing on stress-activated adaptive responses that drive acquired treatment resistance, and designing rational combination co-targeting strategies to create conditional lethality and improve cancer control. He patented several anti-cancer drugs and in 2001 founded OncoGenex Pharmaceuticals to develop OGX-011, an inhibitor of the cell survival gene, clusterin, that potentiates anti-cancer therapies in many cancer models. A randomized trial demonstrated a 7 month gain in overall survival when OGX-011 was combined with docetaxel and 2 Phase III registration trials with OGX-011 are open. OGX-427 is another agent targeting Hsp27 that has demonstrated single agent activity in Phase II studies of castrate resistant prostate cancer, and bladder cancer.
Dr. Stacy Loeb, Assistant Professor of Urology and Population Health, New York University, NY, USA
Dr. Stacy Loeb is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prostate cancer. Dr. Loeb attended medical school at Northwestern University and completed her urology residency training at Johns Hopkins. She has published over 150 peer-reviewed articles and 8 book chapters on prostate cancer. She is on the Editorial Board for the British Journal of Urology International and Reviews in Urology, and authored the chapter on “Early Detection, Diagnosis, and Staging of Prostate Cancer” for Campbell-Walsh Urology. Dr. Loeb also helps teach several courses on prostate cancer for other urologists, and hosts the Men’s Health Show on Sirius XM 81 satellite radio.
Dr Vipul Patel, Director of Robotic Surgery, Professor of Urology, UCF, Director of Urologic Oncology, Florida Hospital Cancer Institute, USA
Dr. Patel attended medical school at Baylor College of Medicine, and did both his residency and fellowship training at the University of Miami. Prior to moving to Florida he was Director of Robotic and Minimally Invasive Urologic Surgery at The Ohio State University.
Yearly, Dr Patel trains hundreds of surgeons on how to safely adopt robotic technology into their surgical practices and leads the robotic training team at the Nicholson Center for Surgical Advancement. He Chairs the World Robotic Symposium, an annual premiere event in robotic surgical education. He is also founder of the Society of Robotic Surgery a multi-specialty organization responsible for education and training.
He is Editor in Chief of The Journal of Robotic Surgery and editor of the first robotic urology textbook. His interests are minimally invasive approaches to the treatment of prostate and kidney cancer, focusing on prostate cancer outcomes. He has performed over 5000 robotic prostatectomies and leads one of the worlds most experienced surgical teams.
Dr Joseph A Smith, Professor and Chairman, Department of Urologic Surgery, Vanderbilt University, Nashville USA
Joseph A Smith, Jr. is Professor and Chairman of the Department of Urologic Surgery at Vanderbilt University in Nashville, Tennessee. He is an AOA graduate of the University of Tennessee Medical School and was chosen the Outstanding Graduate. He performed his surgery residency at the University of Texas Southwestern Medical School at Dallas, his urology residency at the University of Utah, and a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York.
Dr Smith has served as President of the American Board of Urology, President of the Society of Urologic Oncology, President of the Southeastern Section of the American Urologic Association, and Chairman of the Residency Review Committee for Urology. He is a recipient of the Distinguished Contribution Award and the Hugh Hampton Young Award from the American Urologic Association and the SUO achievement medal from the Society of Urologic Oncology. He is Associate Editor of the Journal of Urology and is a member of the American Association of Genitourinary Surgeons and the Clinical Society of GU Surgeons.
He has published over 300 peer reviewed manuscripts, over 100 book chapters, and has edited or co-edited eight textbooks. His professional focus has been on innovative treatment strategies for patients with urologic cancers and introduction and evaluation of technologic advances in urologic surgery.
Dr Patrick C Walsh, University Distinguished Service Professor, The James Buchanan Brady Urological Institute, Johns Hopkins Medicine, USA
Dr. Walsh is best known for his pioneering work in the development of nerve-sparing radical prostatectomy, which has reduced the probability of impotence and incontinence. He is on the editorial board of the New England Journal of Medicine, is a member of the Institute of Medicine of the National Academy of Sciences, and in 1996 he received the Charles F. Kettering Medal from the General Motors Cancer Research Foundation for “the most outstanding recent contributions to the diagnosis and treatment of cancer.” Together with Janet F. Worthington, he authored the best-selling book for lay people Dr. Patrick Walsh’s Guide to Surviving Prostate Cancer, (Hachette Book Group (2012).